News

FDA Chief Says He Wants Gene Therapy Head Prasad to Return
US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head ...
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...
100 days into the job, FDA head talks to CNN about agency goals— and Coke’s switch to sugar
Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...
FDA Ashanti regional head assures public of anonymity for reporting unsafe food sellers
Correspondence from the Ashanti Region Following a recent sensitization program at the Santasi Market as part of the World Food Safety Day, John Laryea Odai-Tettey, Ashanti Region ...
STAT5d
FDA names drug regulator Tidmarsh acting head of biologics center after Prasad’s exit
George Tidmarsh is taking on more responsibilities at FDA after the sudden departure of top official Vinay Prasad.
GlobalData on MSN4d
George Tidmarsh to sub in as FDA CBER head following Prasad’s shock exit
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
FDA Head To ‘Listen To Concerns’ Regarding Coerced Use Of Abortion Pill Widely Available Online
Commissioner Marty Makary said in an interview with Politico’s Dasha Burns that the FDA will “look at the data” surrounding ...
pharmaphorum6d
Vinay Prasad abruptly departs from the FDA
Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...
XBI: Surprise Exit Of A Tough Regulator At The FDA
The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...
BioSpace5d
New CDER Head Tidmarsh Will Sub In At Biologics Group After Prasad’s Exit
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...
Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Sarepta (NASDAQ:SRPT) stock, Replimune (NASDAQ:REPL) stock and Capricor (CAPR) stock surge as FDA's biologics head exits abruptly. Read more here.
Fierce Pharma5d
FDA taps newly appointed George Tidmarsh as acting CBER leader after Vinay Prasad exit
Freshly appointed Center for Drug Evaluation and Research (CDER) leader George Tidmarsh, M.D., Ph.D., will now take on the role of acting director of CBER as well, according to an internal letter from ...